According to our (Global Info Research) latest study, the global Heparin API market size was valued at US$ 1511 million in 2025 and is forecast to a readjusted size of US$ 2508 million by 2032 with a CAGR of 7.6% during review period.
Heparin API is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin API is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin API product is existed in a form of Heparin Sodium API or Heparin Calcium API.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.
The market driver mainly increasing prevalence of conditions such as renal impairment, coronary artery disease, and venous thromboembolism, High demand for anticoagulants, etc.
The expanding healthcare sector, coupled with a rising prevalence of cardiovascular diseases and thrombotic disorders, continues to drive demand for Heparin Active Pharmaceutical Ingredient (API). The growing global aging population and increasing awareness about these medical conditions have further intensified the need for effective anticoagulant therapies. Additionally, advancements in medical research and development, alongside the escalating number of surgical procedures, contribute to the sustained growth of the Heparin API market. While, one of the significant challenges in the Heparin API market is the vulnerability of its supply chain. Dependence on porcine mucosa as the primary source, coupled with supply disruptions due to disease outbreaks and geopolitical factors, poses a risk to consistent availability. Moreover, ensuring the quality and safety of Heparin APIs remains a concern, with regulatory scrutiny focused on preventing adulteration and contamination. Balancing these challenges while navigating competition from alternative anticoagulants and addressing complex production processes poses ongoing difficulties for industry stakeholders.
The classification of Heparin includes Heparin Sodium and Heparin Calcium. In 2024, Heparin Sodium accounted for a revenue share of 96.63% in the global Heparin market. In addition, this product segment is poised to reach US$ 2,228.35 million by 2031 from US$ 1,184.01 million in 2024.
Heparin is widely used for UFH and LMWH. In Heparin market, the LMWH holds an important share in terms of application, and it is expected to reach a value of US$ 1,977.66 million by 2031, at a CAGR of 7.94% during 2025 and 2031.
Europe is the largest consumption place, with a revenue market share nearly 36.86% in 2024. China is the worlds’ largest pig production, which supplied by sufficient raw materials.
North American market for Heparin API is estimated to increase from $ 431.49 million in 2025 to reach $ 671.33 million by 2031, at a CAGR of 7.65% during the forecast period of 2025 through 2031.
Asia-Pacific market for Heparin API is estimated to increase from $ 478.50 million in 2025 to reach $ 799.46 million by 2031, at a CAGR of 8.93% during the forecast period of 2025 through 2031.
Europe market for Heparin API is estimated to increase from $ 537.57 million in 2025 to reach $ 801.22 million by 2031, at a CAGR of 6.88% during the forecast period of 2025 through 2031.
The global key companies of Heparin Active Pharmaceutical Ingredients include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, Bioibérica, Qingdao Jiulong Biopharmaceutical, Changzhou Qianhong Biopharma, and Dongying Tiandong Pharmaceutical, etc. In 2024, the global five largest players hold a share approximately 55.0% in terms of revenue.
This report is a detailed and comprehensive analysis for global Heparin API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Heparin API market size and forecasts, in consumption value ($ Million), sales quantity (Billion Units), and average selling prices (USD/Billion Units), 2021-2032
Global Heparin API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Billion Units), and average selling prices (USD/Billion Units), 2021-2032
Global Heparin API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Billion Units), and average selling prices (USD/Billion Units), 2021-2032
Global Heparin API market shares of main players, shipments in revenue ($ Million), sales quantity (Billion Units), and ASP (USD/Billion Units), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Heparin API
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Heparin API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Pfizer, Nanjing King-friend Biochemical Pharmaceutical, Bioibérica, Changzhou Qianhong Biopharma, Hebei Changshan Biochemical Pharmaceutical, Qingdao Jiulong Biopharmaceutical, Opocrin, Dongying Tiandong Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Heparin API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Heparin Sodium
Heparin Calcium
Market segment by Application
UFH
LMWH
Major players covered
Yantai Dongcheng Pharmaceutical
Shenzhen Hepalink Pharmaceutical
Pfizer
Nanjing King-friend Biochemical Pharmaceutical
Bioibérica
Changzhou Qianhong Biopharma
Hebei Changshan Biochemical Pharmaceutical
Qingdao Jiulong Biopharmaceutical
Opocrin
Dongying Tiandong Pharmaceutical
Aspen Oss
Yino Pharma
Hubei Enoray Biopharmaceutical
Cisen Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Heparin API product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Heparin API, with price, sales quantity, revenue, and global market share of Heparin API from 2021 to 2026.
Chapter 3, the Heparin API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Heparin API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Heparin API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Heparin API.
Chapter 14 and 15, to describe Heparin API sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Heparin API. Industry analysis & Market Report on Heparin API is a syndicated market report, published as Global Heparin API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Heparin API market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.